Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Gain Therapeutics (GANX) Shares Outstanding (Diluted Average) (2020 - 2025)

Gain Therapeutics has reported Shares Outstanding (Diluted Average) over the past 6 years, most recently at $31.4 million for Q3 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $31.4 million for Q3 2025, up 18.17% from a year ago — trailing twelve months through Sep 2025 was $31.4 million (up 18.17% YoY), and the annual figure for FY2024 was $22.9 million, up 75.86%.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $31.4 million at Gain Therapeutics, up from $30.3 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for GANX hit a ceiling of $31.4 million in Q3 2025 and a floor of $4.9 million in Q1 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $12.4 million (2023), compared with a mean of $16.3 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): surged 396.51% in 2021 and later grew 0.06% in 2022.
  • Gain Therapeutics' Shares Outstanding (Diluted Average) stood at $10.2 million in 2021, then grew by 16.9% to $11.9 million in 2022, then rose by 9.49% to $13.0 million in 2023, then surged by 75.86% to $22.9 million in 2024, then skyrocketed by 37.02% to $31.4 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $31.4 million (Q3 2025), $30.3 million (Q2 2025), and $28.7 million (Q1 2025) per Business Quant data.